Vildagliptin (GLIPINOVA) 50mg Tablet 30’s

Vildagliptin (GLIPINOVA) 50mg TABLET – Effective DPP-4 Inhibitor for Type 2 Diabetes Management

About Vildagliptin (GLIPINOVA) 50mg TABLET

Vildagliptin (GLIPINOVA) 50mg TABLET is an oral anti-diabetic medication that belongs to the class of drugs known as Dipeptidyl Peptidase-4 (DPP-4) inhibitors. It is primarily used for the management of Type 2 Diabetes Mellitus (T2DM). Unlike other diabetes medications that may directly increase insulin levels or reduce glucose production, Vildagliptin works by enhancing the body’s own ability to regulate blood sugar levels, making it an effective and well-tolerated choice for many patients.

Often prescribed either as monotherapy or in combination with other anti-diabetic agents such as metformin, sulfonylureas, or insulin, Vildagliptin helps maintain glycemic control and reduce long-term complications associated with diabetes.

---

Indications

Vildagliptin (GLIPINOVA) 50mg TABLET is indicated for:

• Monotherapy for adults with type 2 diabetes mellitus who cannot tolerate metformin or for whom metformin is contraindicated

• Combination therapy with:

  • Metformin, when diet and exercise alone plus metformin do not provide adequate glycemic control

  • Sulfonylureas, when metformin is not suitable

  • Thiazolidinediones, in patients inadequately controlled with these agents

  • Insulin, when stable insulin doses fail to achieve proper glycemic control

Vildagliptin is not used to treat type 1 diabetes or diabetic ketoacidosis.

---

Mechanism of Action

Vildagliptin (GLIPINOVA) 50mg TABLET enhances the function of pancreatic alpha and beta cells by inhibiting the DPP-4 enzyme, which is responsible for the degradation of incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By prolonging the action of these incretin hormones, Vildagliptin helps increase insulin secretion and decrease glucagon production in a glucose-dependent manner.

This targeted mechanism results in:

• Better post-meal glucose control

• Improved overall glycemic management

• Lower risk of hypoglycemia compared to traditional antidiabetics

---

Uses and Benefits of Vildagliptin (GLIPINOVA) 50mg TABLET

1. Effective Glycemic Control

Vildagliptin helps reduce HbA1c levels significantly when used as monotherapy or in combination with other drugs. Its glucose-dependent mechanism ensures that insulin is released only when needed.

2. Low Risk of Hypoglycemia

One of the key advantages of Vildagliptin is its low potential to cause hypoglycemia, especially when used without sulfonylureas.

3. Weight Neutrality

Unlike some diabetes medications that may cause weight gain, Vildagliptin is generally weight neutral, making it ideal for overweight or obese patients.

4. Tolerability

Vildagliptin is generally well-tolerated, with a low incidence of gastrointestinal side effects when compared to metformin.

5. Convenient Dosage

Vildagliptin is usually administered once or twice daily, often making it easier for patients to adhere to therapy.

---

Dosage and Administration of Vildagliptin (GLIPINOVA) 50mg TABLET

The usual recommended dose is 50 mg once or twice daily, depending on the formulation and treatment plan:

• Monotherapy: 50 mg once daily

• Combination with metformin or insulin: 50 mg twice daily

• Combination with sulfonylurea: 50 mg once daily

The dose may vary depending on the patient’s renal function and concurrent medications. Vildagliptin should be taken with or without food and at the same time every day.

---

Precautions

Before using Vildagliptin (GLIPINOVA) 50mg TABLET, consider the following precautions:

• Renal Impairment: Dose adjustment may be necessary in patients with moderate to severe kidney dysfunction.

• Hepatic Impairment: Not recommended in patients with liver disease due to elevated liver enzyme risks.

• Heart Failure: Use cautiously in patients with a history of heart failure.

• Pregnancy and Lactation: Not recommended for use unless clearly needed and prescribed by a doctor.

• Pancreatitis Risk: Rare cases have been reported. Discontinue Vildagliptin immediately if symptoms like severe abdominal pain occur.

Always consult a healthcare professional before starting Vildagliptin (GLIPINOVA) 50mg TABLET, especially if you have existing comorbidities or are on multiple medications.

---

Side Effects

Most patients tolerate Vildagliptin (GLIPINOVA) 50mg TABLET well, but like all medications, it may cause side effects in some individuals:

Common Side Effects:

• Headache

• Dizziness

• Constipation

• Nasopharyngitis

• Mild gastrointestinal discomfort

Rare Side Effects:

• Elevated liver enzymes (monitor liver function regularly)

• Skin rashes

• Edema

• Pancreatitis (rare but serious)

• Joint pain

Patients should report any unusual or persistent symptoms to their physician immediately.

---

Drug Interactions

Vildagliptin (GLIPINOVA) 50mg TABLET has a relatively low potential for drug interactions, but caution is advised when taken with:

• Other oral hypoglycemics (increased risk of hypoglycemia)

• Medications affecting liver enzymes

• Alcohol (may increase risk of pancreatitis or affect glycemic control)

---

Storage Instructions

Proper storage helps maintain the efficacy and safety of Vildagliptin:

• Store at room temperature between 20°C to 25°C

• Keep the tablets in their original blister pack or container

• Protect from excessive moisture and light

• Keep out of reach of children

Do not use expired Vildagliptin, and dispose of it properly according to local pharmaceutical waste guidelines.

---

FAQs

Q: Can Vildagliptin be used with insulin?
Yes, Vildagliptin can be used in combination with insulin when insulin alone does not provide adequate blood sugar control.

Q: Does Vildagliptin cause weight gain?
No. Vildagliptin is generally weight neutral and does not cause weight gain, which is a benefit over other diabetes treatments like sulfonylureas or insulin.

Q: How long does it take for Vildagliptin to work?
Patients may see improved blood glucose levels within a few weeks. Full benefits on HbA1c can be evaluated after 8–12 weeks of consistent use.

---

References and Further Reading

To learn more about Vildagliptin, visit:

• Drugs.com – Vildagliptin

• National Library of Medicine – Vildagliptin Clinical Use

To know more about this product, please contact us.